• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Did CT System Launch Just Shift Rigaku Holdings' (TSE:268A) Investment Narrative?

    Simply Wall St·09/15/2026 16:31:32
    Listen to the news
    • Rigaku Holdings, through Rigaku Corporation, recently introduced the CT Lab HR160, a high resolution X ray CT system using Excillum’s NanoTube N3 source, targeting non destructive 3D inspection in batteries, semiconductors, MLCCs, power electronics and advanced materials.
    • The CT Lab HR160’s 250 nm spatial resolution and adjustable cone beam geometry highlight Rigaku’s focus on higher value lab tools for complex electronic and energy components, where internal inspection is becoming more critical to research, quality control and failure analysis.
    • We will now look at how Rigaku’s investment narrative is influenced by this high resolution CT launch for advanced electronics inspection.

    Scan beyond Rigaku Holdings and this new CT launch by comparing it with other precision hardware players in our hand picked list of 38 robotics and automation stocks focused on advanced inspection and automation.

    What Is Rigaku Holdings' Investment Narrative?

    To own Rigaku Holdings, you need to believe this is a specialist instrumentation business that can keep turning technical credibility into steady orders and service revenue. The CT Lab HR160 fits that story as another high end tool for complex electronics and battery work, where non destructive inspection is becoming more embedded in R&D and quality workflows. In the near term, the key swing factors are how quickly new systems like this convert into shipments, how tight procurement budgets are in semiconductors and batteries, and how effectively Rigaku manages long sales cycles.

    Execution risk is real. Earnings have grown 16.1% per year over five years, yet the latest year showed declining profit and thinner net margins at 9.9% versus 12.3%. A premium P/E of 39.5x against an estimated fair 26.1x, together with a recent share price drop of about 40% over 90 days, leaves little room for operational missteps. The CT Lab HR160 probably supports the medium term story on demand and pricing power, but it does not on its own remove the pressures around capital intensity, external borrowing and share price volatility.

    That said, there is one structural pressure around Rigaku Holdings that could matter more than the CT Lab HR160 launch if ...

    There's only one way to know the right time to buy, sell or hold Rigaku Holdings. Head to Simply Wall St's company report for the latest analysis of Rigaku Holdings's Fair Value.

    TSE:268A 1-Year Stock Price Chart
    TSE:268A 1-Year Stock Price Chart

    Exploring Other Perspectives

    The Simply Wall St Community only supplies two fair value views for Rigaku Holdings, spanning roughly ¥1,341 to ¥2,524 per share. Even this tiny sample shows how far apart private investors can be. Those estimates also predate the CT Lab HR160 launch, so you are comparing older assumptions with a fresh product catalyst.

    Explore another Rigaku Holdings fair value estimate, including one that suggests up to 17% downside from the current price.

    Form Your Own Verdict

    Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking For More Investment Ideas Beyond Rigaku Holdings?

    Once the Rigaku Holdings thesis is clear in your mind, it can help to set it alongside a few other candidates that fit very different checklists. That way you are judging this stock against real trade offs, not in isolation.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.